

May 9, 2005

ATTN: Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: **Blood and Body Fluid Exposure Management Guidelines**

Please note the following revisions to the above guidelines:

Page 5, "Table 1: Fluids capable of transmitting bloodborne pathogens:"

Regarding breast milk and HBV transmission – in addition to the biological plausibility, particularly if nipples are cracked or bleeding, added statement "or if the mother is HBeAg positive."

Page 5, Subsection 5.3.2 "Assess the risk of transmission from the source"

Page 9, Subsection 5.4 "Determine the HIV, HBV, and HCV status of the exposed person:"

- Instruction to advise the source and exposed persons that anti-HIV testing may be done nominally or non-nominally.
- Addition of guidelines for obtaining informed consent from the source and exposed person for blood testing.

Page 18, Subsection 9.2 "HBV exposure:"

Deleted statement that HBIG can be given, if indicated for exposures occurring through consensual adult sex or sharing injection drug equipment. Only hepatitis B vaccine is to be given, if indicated. This recommendation is consistent with the revised guidelines for the control of hepatitis B.

Administrative Circular # 2005:06





HLTH 2339 "Management of Percutaneous or Permucosal Exposure to Blood and Body Fluid/Laboratory Requisition:"

- New note at top of form regarding option of non-nominal HIV testing and reference to the back of the last page of the form for guidelines for obtaining informed consent for blood tests
- New WCB billing code number

HLTH 2340 "Management of Percutaneous or Permucosal Exposure to Blood and Body Fluid Letter for Follow-Up Physician:"

 The notation "results of the above tests will determine the need for further testing" has been added following the section that specifies which baseline blood tests were performed.

Please delete and destroy the following pages from the Communicable Disease Control Manual – Chapter I Management of Specific Diseases:

Blood and Body Fluid Exposure Management Pages 1 – 25

Dated April 2003

HLTH 2339 "Management of Percutaneous" or Permucosal Exposure to Blood and Body Fluid/Laboratory Requisition"

Dated January 2003

HLTH 2340 "Management of Percutaneous" or Permucosal Exposure to Blood and Body Fluid Letter for Follow-Up Physician"

Dated February 2003

Insert the following replacement pages:

Blood and Body Fluid Exposure Management Pages 1 – 26

Dated May 2005

HLTH 2339 "Management of Percutaneous" or Permucosal Exposure to Blood and Body Fluid/Laboratory Requisition"

Dated April 2005





HLTH 2340 "Management of Percutaneous" or Permucosal Exposure to Blood and Body Fluid Letter for Follow-Up Physician"

Dated August 2004

Note: stock of the HLTH 2339 and HLTH 2340 can be ordered from Warehousing Services, 742 Vanalman Avenue, Victoria BC, V8Z 3B5, by e-mail brian.mcneil@gems9.gov.bc.ca or by phone (250) 952-4439.

If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist, at telephone (604) 660-6061, fax (604) 660-0197 or by e-mail to karen.pielak@bccdc.ca

Sincerely,

David Patrick Director **Epidemiology Services** BC Centre for Disease Control

DMP/kka

Dr Perry Kendall pc:

> Provincial Health Officer Ministry of Health Services

Dr. Bob Fisk Medical Consultant Non-Communicable Disease Ministry of Health Panning

Dr. Eric Young

Deputy Provincial Health Officer Ministry of Health Services

Warren O'Briain **Executive Director**

Communicable Disease and

Addiction Prevention

Ministry of Health Services

Valery Dubenko Manager, Communicable Disease Prevention -- Immunization Communicable Disease and Addiction Prevention Ministry of Health Services

